Inuzuka H, et al. (2012) Acetylation-dependent regulation of skp2 function. Cell 150, 179-93 22770219

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S838-p - CDH1 (human) ▲
Modsite: LVFDYEGsGsEAAsL SwissProt Entrez-Gene Orthologous residues CDH1 (human): S838‑p, CDH1 (mouse): S840‑p, CDH1 (rat): S842‑p

S840-p - CDH1 (human) ▲
Modsite: FDYEGsGsEAAsLSs SwissProt Entrez-Gene Orthologous residues CDH1 (human): S840‑p, CDH1 (mouse): S842‑p, CDH1 (rat): S844‑p

S844-p - CDH1 (human) ▲
Modsite: GsGsEAAsLSsLNsS SwissProt Entrez-Gene Orthologous residues CDH1 (human): S844‑p, CDH1 (mouse): S846‑p, CDH1 (rat): S848‑p

S847-p - CDH1 (human) ▲
Modsite: sEAAsLSsLNsSEsD SwissProt Entrez-Gene Orthologous residues CDH1 (human): S847‑p, CDH1 (mouse): S849‑p, CDH1 (rat): S851‑p

S850-p - CDH1 (human) ▲
Modsite: AsLSsLNsSEsDKDQ SwissProt Entrez-Gene Orthologous residues CDH1 (human): S850‑p, CDH1 (mouse): S852‑p, CDH1 (rat): S854‑p

S853-p - CDH1 (human) ▲
Modsite: SsLNsSEsDKDQDYD SwissProt Entrez-Gene Orthologous residues CDH1 (human): S853‑p, CDH1 (mouse): S855‑p, CDH1 (rat): S857‑p

K68-ac - SKP2 (human) ▲

Modsite: HPEsPPRkRLkskGs SwissProt Entrez-Gene Orthologous residues SKP2 (human): K68‑ac, SKP2 (mouse): K68‑ac Characterization Methods used to characterize site in vivo:  immunoprecipitation, mass spectrometry, modification-specific antibody, mutation of modification site, western blotting Relevant cell lines - cell types - tissues:  HEK293T (epithelial), HeLa (cervical), MEF (fibroblast) Cellular systems studied:  cell lines Species studied:  human, mouse Enzymes shown to modify site in vitro:  Type Enzyme DEACETYLASE SIRT3 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes DEACETYLASE SIRT3 (human) co-immunoprecipitation, siRNA inhibition of enzyme, transfection of wild-type enzyme, transfection of inactive enzyme, pharmacological inhibitor of upstream enzyme, genetic knockout/knockin of upstream enzyme ACETYLTRANSFERASE p300 (human) co-immunoprecipitation, transfection of wild-type enzyme, activation of upstream enzyme, pharmacological inhibitor of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes CBP (human) no change compared to control GCN5 (human) no change compared to control insulin increase garcinol insulin inhibit treatment-induced increase siRNA increase Sirt3-siRNA increases acetylation SIRT4 (human) no change compared to control siRNA used Downstream Regulation Effect of modification (function):  intracellular localization, protein stabilization Effect of modification (process):  carcinogenesis, induced, cell motility, induced Comments:  Skp2 cytoplasmic localization

K71-ac - SKP2 (human) ▲

Modsite: sPPRkRLkskGsDkD SwissProt Entrez-Gene Orthologous residues SKP2 (human): K71‑ac, SKP2 (mouse): K71‑ac Characterization Methods used to characterize site in vivo:  immunoprecipitation, modification-specific antibody, mutation of modification site, western blotting Relevant cell lines - cell types - tissues:  HEK293T (epithelial), HeLa (cervical), MEF (fibroblast) Cellular systems studied:  cell lines Species studied:  human, mouse Enzymes shown to modify site in vitro:  Type Enzyme DEACETYLASE SIRT3 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes DEACETYLASE SIRT3 (human) co-immunoprecipitation, siRNA inhibition of enzyme, transfection of wild-type enzyme, transfection of inactive enzyme, pharmacological inhibitor of upstream enzyme, genetic knockout/knockin of upstream enzyme ACETYLTRANSFERASE p300 (human) co-immunoprecipitation, transfection of wild-type enzyme, activation of upstream enzyme, pharmacological inhibitor of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes CBP (human) no change compared to control GCN5 (human) no change compared to control insulin increase garcinol insulin inhibit treatment-induced increase siRNA increase Sirt3-siRNA increases acetylation SIRT4 (human) no change compared to control siRNA used Downstream Regulation Effect of modification (function):  intracellular localization, protein stabilization Effect of modification (process):  carcinogenesis, induced, cell motility, induced Comments:  Skp2 cytoplasmic localization

S72-p - SKP2 (human) ▲

Modsite: PPRkRLkskGsDkDF SwissProt Entrez-Gene Orthologous residues SKP2 (human): S72‑p, SKP2 (mouse): G72‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  HeLa (cervical) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE Akt1 (human) activation of upstream enzyme, phospho-antibody Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes insulin increase

S75-p - SKP2 (human) ▲
Modsite: kRLkskGsDkDFVIV SwissProt Entrez-Gene Orthologous residues SKP2 (human): S75‑p, SKP2 (mouse): S75‑p

K68-ac - SKP2 (mouse) ▲

Modsite: HPQsPPRkRVkGKGS SwissProt Entrez-Gene Orthologous residues SKP2 (human): K68‑ac, SKP2 (mouse): K68‑ac Characterization Methods used to characterize site in vivo:  immunoprecipitation, mass spectrometry, modification-specific antibody, mutation of modification site, western blotting Relevant cell lines - cell types - tissues:  HEK293T (epithelial), HeLa (cervical), MEF (fibroblast) Cellular systems studied:  cell lines Species studied:  human, mouse Enzymes shown to modify site in vitro:  Type Enzyme DEACETYLASE SIRT3 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes DEACETYLASE SIRT3 (human) co-immunoprecipitation, siRNA inhibition of enzyme, transfection of wild-type enzyme, transfection of inactive enzyme, pharmacological inhibitor of upstream enzyme, genetic knockout/knockin of upstream enzyme ACETYLTRANSFERASE p300 (human) co-immunoprecipitation, transfection of wild-type enzyme, activation of upstream enzyme, pharmacological inhibitor of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes CBP (human) no change compared to control GCN5 (human) no change compared to control insulin increase garcinol insulin inhibit treatment-induced increase siRNA increase Sirt3-siRNA increases acetylation SIRT4 (human) no change compared to control siRNA used Downstream Regulation Effect of modification (function):  intracellular localization, protein stabilization Effect of modification (process):  carcinogenesis, induced, cell motility, induced Comments:  Skp2 cytoplasmic localization

K71-ac - SKP2 (mouse) ▲

Modsite: sPPRkRVkGKGSDKD SwissProt Entrez-Gene Orthologous residues SKP2 (human): K71‑ac, SKP2 (mouse): K71‑ac Characterization Methods used to characterize site in vivo:  immunoprecipitation, modification-specific antibody, mutation of modification site, western blotting Relevant cell lines - cell types - tissues:  HEK293T (epithelial), HeLa (cervical), MEF (fibroblast) Cellular systems studied:  cell lines Species studied:  human, mouse Enzymes shown to modify site in vitro:  Type Enzyme DEACETYLASE SIRT3 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes DEACETYLASE SIRT3 (human) co-immunoprecipitation, siRNA inhibition of enzyme, transfection of wild-type enzyme, transfection of inactive enzyme, pharmacological inhibitor of upstream enzyme, genetic knockout/knockin of upstream enzyme ACETYLTRANSFERASE p300 (human) co-immunoprecipitation, transfection of wild-type enzyme, activation of upstream enzyme, pharmacological inhibitor of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes CBP (human) no change compared to control GCN5 (human) no change compared to control insulin increase garcinol insulin inhibit treatment-induced increase siRNA increase Sirt3-siRNA increases acetylation SIRT4 (human) no change compared to control siRNA used Downstream Regulation Effect of modification (function):  intracellular localization, protein stabilization Effect of modification (process):  carcinogenesis, induced, cell motility, induced Comments:  Skp2 cytoplasmic localization